A cne rosacea is a chronic skin disorder that presents with symmetrical facial flushing and edema, leading to telangiectases that can later develop into papules, pustules, and persistent erythema. Tissue overgrowth of the nose (rhinophyma) also may occur. Conjunctival areas of involvement are known to occur, especially in the severest forms of acne rosacea. The prevalence of acne rosacea has been estimated to be about 10%, 1,2 with women affected more often than men.
Although the cause of this disorder was originally thought to be a vascular phenomenon aggravated by degenerative changes in pilosebaceous units, [1] [2] [3] infectious causes also have been theorized 1 (eg, Helicobacter pylori infection in association with other gastrointestinal disorders, 4 Demodex folliculorum infestation 5 ). Hormonal influences, emotional stress, increased humoral vasoactive mediators such as substance P, food intolerance, and the degenerative effect of the sun constitute other postulated causes. [6] [7] [8] Effective treatment (improvement in 80%-90% of cases) of acne rosacea has been achieved with oral tetracyclines or topical metronidazole. Combining these 2 modalities achieves a more rapid response and is a widely used method of modern day therapy. 3, 4, 9, 10 Oral use of azithromycin 3 times weekly also has been successfully used to treat acne vulgaris, 11, 12 an observation that suggested an infectious agent may play an active role in the etiology ® Therapeutics for the Clinician of acne rosacea. We were the first to report that C pneumoniae may be involved in the pathogenesis of acne rosacea, based on a case of an elderly patient with persistent acne rosacea who responded to azithromycin therapy. Results of a skin biopsy taken of an active lesion prior to therapy tested positive for C pneumoniae antigen using species-specific monoclonal antibodies, which prompted us to conduct a more thorough investigation of the role C pneumoniae may play in the etiology of acne rosacea.
A study of 10 different patients, not reported previously, found azithromycin to be safe and effective for the treatment of acne rosacea. 13 The aim of this study was 2-fold: first, to examine the effects of oral azithromycin in subjects with acne rosacea; second, to investigate whether C pneumoniae, an infectious agent, played a role in the etiology of acne rosacea in those subjects treated with oral azithromycin. We used direct-antigen detection methods on tissue biopsy specimens to document the presence of C pneumoniae antigen, and we used serology tests to detect antibody to C pneumoniae.
Materials and Methods
Study Design-A series of 10 adults (6 men) were selected in an office setting to receive oral azithromycin monotherapy for the treatment of acne rosacea (age range, 34-72 years). The subjects agreed to take 250 mg of oral azithromycin 3 times weekly (Mondays, Wednesdays, and Fridays), a dosage regimen shown to be effective for the treatment of acne vulgaris. 11, 12 An academic institutional review board approved the study protocol, and all subjects signed an informed consent form. Subjects were encouraged to regularly wash involved skin with a commercially available soap substitute, the sole topical agent allowed. The subjects were not receiving treatment for acne rosacea before starting azithromycin nor were they taking any medication that could either exacerbate or improve clinical signs and symptoms of acne rosacea. The subjects reported no history of using azithromycin for this indication. Subject demographics, clinical stage, evidence of eye involvement, biopsy site, clinical response, and duration of treatment (signaled by time until follow-up), appear in the Histologic Studies-Routine histologic studies were assessed from formalin-fixed paraffin-embedded sections that were stained with hematoxylin and eosin. Immunocytochemistry analysis for detection of Chlamydia was performed on deparaffinized sections, using the avidin-biotin-peroxidase complex immunostaining system with the genus-specific monoclonal antibody CF2, species-specific anti-Chlamydia trachomatis monoclonal antibody KK-12, and speciesspecific anti-C pneumoniae clone 161.
Serologic Studies-Serum samples were obtained at the time of the initial office visit. Sera were tested for immunoglobulin (Ig) G and IgM antibodies against C pneumoniae and C trachomatis by microimmunofluorescence assay.
14 Subjects with a serovar-specific IgM antibody titer of 1:8 or higher or an IgG titer of 1:8 or higher were considered to have a positive response to C pneumoniae or C trachomatis in this study.
Results
Clinical Outcome Posttreatment-Prior to initiation of therapy, the possible side effects of azithromycin were explained to the subjects, including nausea, gastric discomfort, vaginitis, and possible rash. No subjects complained of any symptoms associated with the medication use. In 8 of 9 treated subjects, evaluation of azithromycin treatment occurred after 5 to 19 weeks of treatment (Table) . Subject 7 was lost to follow-up, and subject 3 did not begin treatment due to pregnancy. The initial severity of disease was defined as severe in subjects 2, 5, 8, 9, and 10 ( Figure 1 ). Their clinical response was rated as marked.
Histologic Studies-Before therapy began, C pneumoniae antigen was detected in biopsy Detection of Chlamydia pneumoniae in subjects with acne rosacea using the avidin-biotin-peroxidase complex immunostaining system. Monoclonal antibody species-specific for C pneumoniae (A, original magnification 340; B and C, original magnifications 3100). No primary antibody (control)(D, original magnification 3100), species-specific Chlamydia trachomatis monoclonal antibody KK-12 (E, original magnification 3100), and genus-specific monoclonal antibody CF-2 (F, original magnification 3100). Typical inflammatory infiltrates of subjects with acne rosacea with hematoxylin and eosin staining (G2I; original magnifications 310, 40, and 100, respectively).
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specimens from active lesions, mostly malar specimens, in subjects by immunoperoxidase technique in 4 of 10 tissues tested (Figure 2 ). These same 4 subjects also were positive for C pneumoniae by serology. All subjects with C pneumoniae antigen by immunoperoxidase technique also were positive for C pneumoniae serology, which strongly suggests that C pneumoniae may indeed play a role in the inflammatory responses observed in the histology, and thus, its presence may correlate clinically with active rosacea. Subjects 1 and 3 had a mild inflammatory infiltration; all others had moderate to heavy polymorphonuclear neutrophils, lymphocytes, and plasma cells throughout the biopsy. 15, 16 A favorable clinical response following the systemic use of azithromycin was noted in all 9 subjects treated.
Serologic Studies-No IgM antibodies for C pneumoniae were detected in any of the 10 subjects. However, IgG was elevated (titer ≥1:16) in 8 of 10 subjects. One subject (subject 9) also (Table) .
Comment
Acne rosacea, a chronic disorder, poses a challenge to physicians. There is a need to search for new and effective therapies. When our subjects initially presented with the first symptoms of disease, there was no noted association of any recent respiratory illness. However, subsequent questioning gave possible indications that some of the subjects had a prolonged respiratory ailment before their presentation with acne rosacea. It was hard to determine if this information was clinically reliable because it is possible that the information was offered to please the interviewer. C pneumoniae is associated with asthma, chronic lung disease, and many other conditions. The organism's presence also has been found in atherosclerotic plaques. 15 Our interest was in determining whether C pneumoniae plays an etiologic role in promoting chronic infection and inflammation in acne rosacea. Subjects were immediately treated with an oral course of azithromycin following the skin biopsy procedure (except subject 3). Azithromycin was chosen because it has been previously shown to be safe and effective in the treatment of acne vulgaris.
Of the 10 subjects in our study with acne rosacea, eight had at least one positive C pneumoniae test, suggesting a major role of C pneumoniae in acne rosacea. Serologic tests showed, as expected, no IgM for C pneumoniae, but an elevated IgG was demonstrated in 8 of 10 subjects. The subjects in which C pneumoniae antigen was detected by immunoperoxidase technique also were positive by serology. C pneumoniae was not detected in peripheral blood mononuclear cells (data not shown) using polymerase chain reaction. All samples contained DNA (b-globulin) as the internal control. Negative polymerase chain reaction findings were most likely caused by relatively high levels of red blood cells (known to be an inhibitory factor) in the samples. Subjects 1, 6, 8, and 10 had antigenpositive tissues. Subjects 1, 6, and 10 also had eye involvement, as well as C pneumoniae antibody by serology. Conjunctival disease often is associated with the more severe forms of the disease.
The favorable clinical response with azithromycin use in our study suggests the need for further investigation with clinical trials to study long-term efficacy and tolerability. The precise role of C pneumoniae, which currently remains unknown, needs to be elucidated. The organism's presence in the skin lesions of some subjects with acne rosacea deserves larger scale investigation. Further studies will investigate eye secretions for local antibody production. Cultures and the use of nucleic acid amplification tests as diagnostic tests to detect the presence of organisms in the eye and other involved tissues will be employed. These approaches will provide crucial evidence to support that C pneumoniae plays a significant role in the clinical manifestation of acne rosacea.
